After a median follow-up of 45.3 months, the atezolizumab group showed a better OS trend than the best supportive care group among patients with PD-L1 TC ≥1% with stage II-IIIA NSCLC (5-year OS rate: 76.8% vs. 67.5%). Here, CD274 is linked to non-small cell lung carcinoma.